Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Qilu Hospital of Shandong University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07172685CT.gov Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC | — | Recruiting | — | — | — |
NCT05753046CT.gov Laparoscopic TAP Block During Robotic Assisted Laparoscopic Radical Prostatectomy for Improvement in Postoperative Pain | — | Enrolling By Invitation | — | — | — |
NCT04729114CT.gov A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03606889CT.gov Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia | — | Terminated | — | — | — |
NCT03177460CT.gov Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer | — | Completed | — | — | — |
NCT04147806CT.gov A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02491411CT.gov Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | — | Terminated | — | — | — |
NCT02441894CT.gov Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer | — | Completed | — | — | — |
NCT02928432CT.gov SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone | — | Completed | — | — | — |
Show 11 more trialsShow fewer
NCT01188187CT.gov Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer | — | Completed | — | — | — |
NCT01036594CT.gov Ketoconazole and Dexamethasone in Prostate Cancer | — | Completed | — | — | — |
NCT00559481CT.gov Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy | — | Withdrawn | — | — | — |
NCT00427999CT.gov Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer | — | Completed | — | — | — |
NCT00460031CT.gov Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | — | Completed | — | — | — |
NCT00939510CT.gov Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00060398CT.gov Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00316927CT.gov Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00024167CT.gov Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT01250717CT.gov Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer | — | Completed | — | — | — |
NCT00006002CT.gov SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Qilu Hospital of Shandong University | Approved | BB · 69 |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BBB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BBB |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BB |
| Goserelin | Bayer | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Flutamide | VA Office of Research and Development | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | BBB · 78 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/dexasone-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →